Izzat M B, Yim A P, El-Zufari M H
Division of Cardiothoracic Surgery, Department of Surgery, Prince of Wales Hospital, Shatin, N.T., Hong Kong.
Ann Thorac Cardiovasc Surg. 1998 Aug;4(4):205-8.
We reviewed our experience over a 12 month period with using minimally invasive direct coronary artery bypass (MIDCAB) for the management of high-risk patients with three-vessel coronary artery disease. Twenty patients (4 females, mean age 67 years) received left internal mammary artery (LIMA) grafts to the left anterior descending (LAD) coronary artery. Associated co-morbidity included: severe chronic renal failure, severe extensive arteriopathy, chronic obstructive airway disease, poor general condition and severely impaired left ventricular function. There was one early postoperative mortality and no other cardiac-related morbidity. Graft patency investigated, using angiography was 90%, and 5 patients underwent follow-up angioplasty to other coronary arteries. All patients remain entirely angina free at a follow-up period between 3 and 12 months. We conclude that MIDCAB is a safe and effective approach for managing high-risk patients with three-vessel coronary artery disease.
我们回顾了为期12个月使用微创直接冠状动脉旁路移植术（MIDCAB）治疗高危三支冠状动脉疾病患者的经验。20例患者（4例女性，平均年龄67岁）接受了左乳内动脉（LIMA）移植至左前降支（LAD）冠状动脉。相关合并症包括：严重慢性肾衰竭、严重广泛性动脉病变、慢性阻塞性气道疾病、一般状况差和左心室功能严重受损。术后有1例早期死亡，无其他心脏相关并发症。通过血管造影检查的移植血管通畅率为90%，5例患者接受了其他冠状动脉的随访血管成形术。所有患者在3至12个月的随访期内均完全无心绞痛。我们得出结论，MIDCAB是治疗高危三支冠状动脉疾病患者的一种安全有效的方法。
